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Sydnones have gained importance not only due to their struc-
tural features as 1,3-dipoles, but also because of their biological
signiﬁcance. During the past, many interesting data have been
obtained on the structures (Cooper et al., 2005; Hasek et al.,1979), reactivities (Dumitrascu et al., 2002; Cherepanov and
Kalinin, 2000), physicochemical pharmacological properties
(Sasaki and Ishibashi, 1990; Handa et al., 1997; Moustafa
et al., 2004; Dunkley and Thoman, 2003) of sydnones. Couma-
rin nucleus has been the aim of many workers as most of its
derivatives were proved to be active as antitumor, antibacterial,
antifungal, anticoagulant and antiinﬂammatory agents (Raev
et al., 1990; El-Agrody et al., 2001; Emmanuel-Giota et al.,
2001).On the other hand thiazole derivatives have been reported
to be biologically versatile compounds displaying wide range of
antiinﬂammatory, anticancer, antibacterial, antifungal and
antiallergic properties (Kennedy and Thornes, 1997; Andrewi
et al., 1996; Anu et al., 1977; Roscoe et al., 1971; Martin et al.,
1997).
Table 1 Synthesis of thiazole derivatives.
Compounds Method 1 Method 2 M.P. (C)
Time (h) Yield (%) Time (h) Yield (%)
4a 4.10 56 3.00 80 184–85 a
4b 5.10 60 2.50 72 233–35 a
4c 4.30 52 2.00 74 228–29
4d 4.40 55 2.35 68 212–13 a
4e 5.15 58 2.45 75 223–24 a
4f 4.50 50 2.15 71 216–17
4g 5.00 54 2.30 73 196–97
4h 5.35 62 3.15 81 258–59
4i 4.40 58 2.55 76 240–41
4j 5.25 56 3.20 69 173–74
4k 5.05 49 3.00 75 206–07
4l 4.00 53 2.20 79 191–92
4m 4.20 57 2.50 73 156–57
4n 5.10 55 3.30 78 213–14
4o 5.30 52 2.35 72 179–80
4p 4.20 50 3.10 76 188–89
4q 5.15 53 3.40 80 244–45
4r 4.20 57 2.35 81 217–18
a Kalluraya and Rai (2004).
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for hydrolyzing polysaccharides such as dietary starch.
Inhibition of this enzyme could be extremely beneﬁcial in dia-
betic patients because it could lower the glucose levels in the
blood. One of the therapeutic approaches adopted thus far
to ameliorate postprandial hyperglycemia involves the retarda-
tion of glucose absorption via the inhibition of carbohydrate-
hydrolyzing enzymes viz., a-glycosidase and a-amylase in the
digestive organs (Bhandari et al., 2008). The powerful syn-
thetic a-glucosidase and a-amylase inhibitors such as acarbose,
miglitol and voglibose, function directly in reducing the sharp
increases in glucose levels that occur immediately after food in-
take (Saito et al., 1998; Sels et al., 1999; Stand et al., 1999).
However, the continuous use of these synthetic agents should
be limited because these agents may induce side effects such
as ﬂatulence, abdominal cramps, vomiting and diarrhoea
(Hanefeld, 1998). Additionally, there have been some reports
describing an increased incidence of renal tumors, serious he-
patic injury and acute hepatitis (Diaz-Gutierrez et al., 1998;
Charpentier et al., 2000). Therefore, a number of studies have
been conducted in the search for naturally derived a-glycosi-
dase and a-amylase inhibitors that induce no deleterious side
effects (Matsui et al., 2007; Kim et al., 2008; Heo et al., 2009).
Several synthetic methods have been reported for the prep-
aration of thiazoles (Hantzsch and Weber, 1887; Hantasch,
1888; Dodson and Kingh, 1945; King and Halvacek, 1950;
Rajeswar Rao et al., 1996). Although some of these methods
are useful, the majority of them suffer from at least one of
the disadvantages such as low yield, prolonged reaction time,
use of toxic organic solvents, excess of reagents and catalysts,
high cost and susceptibility to moisture. In recent years, evolu-
tion of chemical reactions involving less hazardous, environ-
mentally acceptable and recyclable catalytic systems have
gained considerable attention both in industry and academia
(Wang et al., 2006; Ando et al., 1982; Kabalka et al., 1999,
2001; Hosseinzadeh et al., 2008; Silva et al., 2008; Boruah
et al., 2007; Ge and Hu, 2007; Movassagh and Shokri, 2005;
yadav et al., 2001; Blass et al., 1999; Blass, 2002). Generally,
the solid acid catalysts are mainly based on clay and silica
(Cornelis and Laszlo, 1994; Clark and Marquarie, 1998;
Varma et al., 1999). In terms of convenience, silica based cat-
alysts are inexpensive, easy to prepare and insoluble in most of
the organic solvents so as to recover and recycle from the reac-
tions. Further, this reagent is safe, easy to handle, non-toxic,
environmentally benign and presents fewer disposal problems.
In view of this, silica sulfuric acid has been used as a solid acid
catalyst in many reactions such as nitration of aromatic com-
pounds (Riego et al., 1996), oxidation of thiols to disulﬁdes
(Zolﬁgol, 2001), three component Biginelli reaction (Salehi
et al., 2003), preparation of diacetates (Hajipour et al., 2005)
and deprotection of tetrahydropyranyl ethers (Hajipour
et al., 2006) acetals and ketals (Mirjalili et al., 2002). However,
to the best of our knowledge, the synthesis of sydnone deriva-
tives containing thiazole and coumarin entities using silica
sulfuric acid as a catalyst has not been reported so far.
In continuation of our work aiming at the synthesis of syd-
none derivatives appended to coumarin, we herein report a
green reaction of thiosemicarbazone (2a–f), with 3-bromoace-
tyl-(6-substituted)-coumarin (3g–i) at a time in dry ethanol
using catalyst silica sulfuric acid to afford a series of thiazole
derivatives (4a–r) appended to coumarin and sydnone. Be-
cause, it was envisaged that the two pharmacophores if linkedtogether would generate novel molecular templates which are
likely to exhibit interesting biological properties in animal
models. The present study also includes testing of target com-
pounds for their antidiabetic activity (a-amylase inhibition)
and DNA cleavage analyses.
2. Experimental
2.1. General
Melting points were determined in open capillaries. IR (KBr)
spectra were recorded on FT-IR spectrometer. 1H NMR spec-
tra (CDCl3) were recorded using Varian-300 MHz FT-NMR
spectrometer with TMS as an internal standard. Mass spectra
were recorded on GCMS-SC/AD/17-004 instrument. Silica
sulfuric acid was prepared according to the reported method
(Zolﬁgol, 2001).
2.2. General methods of preparation of 4-({2-[4-(6-substituted-
coumarin-3-yl)-1,3-thiazol-2-yl]-hydrazinylidene}-methyl/
ethyl)-3-arylsydnones (4a-r)
2.2.1. Method 1
3-Aryl-4-formyl/acetylsydnone (1a-f) (0.10 mol) dissolved in
alcohol was added into a solution of thiosemicarbazide
(0.20 mol) in hot water. The contents were stirred for 5 min
and the precipitate thus formed was separated and ﬁltered.
Recrystalization from 50% aqueous alcohol yielded the crys-
tals of (2a-f). The compound (2a-f) was then reﬂuxed with
equimolar quantity of (6-substituted)-3-bromoacetylcoumarin
(3g-i) and silica sulfuric acid (5 mol%) in dry ethanol for an
appropriate time (as indicated in Table 1). After completion
of the reaction the catalyst was removed by ﬁltration and the
ﬁltrate was poured into ice cold water. The crude product
(4a-r) formed was ﬁltered and recrystallized from ethanol to
obtain yellow crystals.
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A mixture of 3-aryl-4-formyl/acetylsydnone (1a-f) (0.01 mol),
thiosemicarbazide (0.01 mol) and 3-bromoacetyl-(6-substi-
tuted)-coumarin (3g-i) (0.01 mol), was dissolved in dry ethanol
(50 ml) and was reﬂuxed with silica sulfuric acid (5 mol%).
The progress of the reaction was monitored by TLC and after
completion of the reaction (Table 1), the catalyst was ﬁltered
and the solvent was removed under vacuo to yield the crude
product, which was then recrystallized from ethanol to get
the needles of (4a-r).
2.2.2.1. 4-({2-[4-(Coumarin-3-yl)-1,3-thiazol-2-yl]-hydraziny-
lidene}methyl)-3-phenylsydnone (4a). Yield 80%, m.p. 184–
185 C. IR (KBr): t 3445 (NH), 1738 (sydnone C‚O), 1720
(coumarin C‚O), 1612 (C‚N) cm1. 1H NMR (300 MHz,
CDCl3, 25 C, TMS): d= 7.35 (s, 1H, C50–H), 7.38–7.95 (m,
10H, Ar–H), 8.48 (s, 1H, H–C‚N) ppm; MS: m/z = 433.
Anal. calcd for C21H13N5O4S: C, 58.46; H, 3.04; N, 16.23.
Found: C, 58.10; H, 3.00; N, 16.18.
2.2.2.2. 4-({2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-
yl]hydrazinylidene}methyl)-3-phenyl sydnone (4b). Yield
72%, m.p. 233–234 C. IR (KBr): t 3448 (NH), 1740 (sydnone
C‚O), 1725 (coumarin C‚O), 1618 (C‚N) cm1. 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 7.10 (s, 1H, C50–H),
7.30–7.82 (m, 10H, Ar–H), 8.41 (s, 1H, H–C‚N) ppm; MS:
m/z = 515 (M+2, 18), 513 (M+, 22). Anal. calcd for
C21H12BrN5O4S: C, 49.42; H, 2.37; N, 13.72. Found: C,
49.35; H, 2.40; N, 13.68.
2.2.2.3. 4-({2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}methyl)-3-phenylsydnone (4c). Yield 74%,
m.p. 196–197 C. IR (KBr): t 3446 (NH), 1738 (sydnone
C‚O), 1721 (coumarin C‚O), 1615 (C‚N) cm1. 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 7.00 (s, 1H, C50–
H), 7.40–7.88 (m, 10H, Ar–H), 8.35 (s, 1H, H–C‚N) ppm;
MS: m/z = 471 (M+2, 7), 469 (M+, 20). Anal. calcd for
C21H12ClN5O4S: C, 54.14; H, 2.60; N, 15.03. Found: C,
54.10; H, 2.56; N, 14.96.
2.2.2.4. 4-({2-[4-(Coumarin-3-yl)-1,3-thiazol-2-yl]-hydraziny-
lidene}methyl)-3-p-tolylsydnone (4d). Yield 68%, m.p. 212–
213 C. IR (KBr): t 3452 (NH), 1746 (sydnone C‚O), 1728
(coumarin C‚O), 1610 (C‚N) cm1, 1H NMR (300 MHz,
CDCl3, 25 C, TMS): d= 2.8 (s, 3H, CH3), 6.55 (s, 1H, C50–
H), 7.00–7.70 (m, 10H, Ar–H), 8.20 (s, 1H, H–C‚N) ppm;
MS: m/z = 446. Anal. calcd for C22H15N5O4S: C, 59.32; H,
3.39; N, 15.72. Found: C, 59.22; H, 3.34; N, 15.68.
2.2.2.5. 4-({2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}methyl)-3-p- tolylsydnone (4e). Yield 75%,
m.p. 223–224 C. IR (KBr): t 3458 (NH), 1749 (sydnone
C‚O), 1718 (coumarin C‚O), 1622 (C‚N) cm1, 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 3.00 (s, 3H,
CH3), 6.15 (s, 1H, C50–H), 7.10–7.80 (m, 8H, Ar–H), 8.28 (s,
1H, H–C‚N) ppm; MS: m/z = 528 (M+2, 13), 526 (M+,
17). Anal. calcd for C22H14BrN5O4S: C, 50.39; H, 2.69; N,
13.36. Found: C, 50.30; H, 2.62; N, 13.30.
2.2.2.6. 4-({2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}methyl)-3-p-tolylsydnone (4f). Yield 71%,m.p. 236–237 C. IR (KBr): t 3453 (NH), 1745 (sydnone
C‚O), 1727 (coumarin C‚O), 1618 (C‚N) cm1, 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 2.90 (s, 3H,
CH3), 6.35 (s, 1H, C50–H), 7.15-7.75 (m, 8H, Ar–H), 8.25 (s,
1H, H–C‚N) ppm; MS: m/z = 484 (M+2, 12), 482 (M+,
34). Anal. calcd for C22H14ClN5O4S: C, 54.83; H, 3.35; N,
14.53. Found: C, 54.78; H, 3.30; N, 14.49.
2.2.2.7. 3-(p-Chlorophenyl)-4-({2-[4-(coumarin-3-yl)-1,3-thia-
zol-2-yl]hydrazinylidene}methyl)-sydnone (4g). Yield 73%,
m.p. 208–209 C. IR (KBr): t 3447 (NH), 1742 (sydnone
C‚O), 1722 (coumarin C‚O), 1615(C‚N) cm1, 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 6.45 (s, 1H, C50–H),
7.40–7.94 (m, 9H, Ar–H), 8.44 (s, 1H, H–C‚N) ppm; MS:
m/z = 469 (M+2, 9), 467 (M+, 25). Anal. calcd for
C21H14ClN5O4S: C, 53.91; H, 3.02; N, 14.97. Found: C,
53.85; H, 2.95; N, 14.90.
2.2.2.8. 4-({2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-yl]
hydrazinylidene}methyl)-3-p-chlorophenylsydnone (4h). Yield
81%, m.p. 216–217 C. IR (KBr): t 3449 (NH), 1744 (sydnone
C‚O), 1723 (coumarin C‚O), 1623 (C‚N) cm1, 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 6.20 (s, 1H, C50–H),
7.42–8.00 (m, 8H, Ar–H), 8.38 (s, 1H, H–C‚N) ppm; MS:
m/z = 549 (M+4, 11), 547 (M+2, 35), 545 (M+, 27). Anal.
calcd for C21H11ClBrN5O4S: C, 46.13; H, 2.40; N, 12.81.
Found: C, 46.08; H, 2.35; N, 12.80.
2.2.2.9. 4-({2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}methyl)-3-p-chlorophenylsydnone (4i). Yield
76%, m.p. 211–212 C. IR (KBr): t 3447 (NH), 1743 (sydnone
C‚O), 1726 (coumarin C‚O), 1620 (C‚N) cm1, 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 6.30 (s, 1H, C50–H),
7.38–7.94 (m, 8H, Ar–H), 8.31 (s, 1H, H–C‚N) ppm; MS:
m/z = 505 (M+4, 9), 503 (M+2, 22), 501 (M+, 36); Anal. calcd
for C21H11Cl2N5O4S: C, 50.41; H, 2.22; N, 14.00. Found: C,
50.37; H, 2.20; N 13.96.
2.2.2.10. 4-(1-{2-[4-(Coumarin-3-yl)-1,3-thiazol-2-yl]hydraz-
inylidene}ethyl)-3-phenylsydnone (4j). Yield 69%, m.p. 191–
192 C. IR (KBr): t 3428 (NH), 1732 (sydnone C‚O), 1728
(coumarin C‚O), 1595 (C‚N), cm1, 1H NMR (300 MHz,
CDCl3, 25 C, TMS): d= 2.42 (s, 3H, CH3), 7.41 (s, 1H,
C50–H), 7.66–8.60 (m, 10H, Ar–H), 11.61 (s, 1H, NH) ppm;
MS: m/z = 445. Anal. calcd for C22H15N5O4S: C, 59.32; H,
3.39; N, 15.72. Found: C, 59.28; H, 3.34; N, 15.70.
2.2.2.11. 4-(1-{2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-
yl]hydrazinylidene}-ethyl)-3-phenylsydnone (4k). Yield 75%,
m.p. 226–227 C. IR (KBr): t 3435 (NH), 1738 (sydnone
C‚O), 1724 (coumarin C‚O), 1610 (C‚N) cm1, 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 2.39 (s, 3H,
CH3), 7.24 (s, 1H, C50–H), 7.52–8.18 (m, 9H, Ar–H), 10.88
(s, 1H, NH) ppm; MS: m/z = 527 (M+2, 22.40), 525 (M+,
27.30). Anal. calcd for C22H14BrN5O4S: C, 50.39; H, 2.69;
N, 13.36. Found: C, 50.35; H, 2.65; N, 13.34.
2.2.2.12. 4-(1-{2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-
yl]hydrazinylidene}ethyl)-3-phenylsydnone (4l). Yield 79%,
m.p. 203–204 C. IR (KBr): t 3432 (NH), 1735 (sydnone
C‚O), 1730 (coumarin C‚O), 1600 (C‚N) cm1. 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 2.27 (s, 3H,
Synthesis of 3-aryl-4-({2-[4-(6-substituted-coumarin-3-yl)-1,3-thiazol-2-yl]hydrazinylidene}methyl/ethyl) S309CH3), 7.28 (s, 1H, C50–CH), 7.36–8.12 (m, 9H, Ar–H), 11.12 (s,
1H, NH) ppm; MS: m/z = 483 (M+2, 12.60), 481 (M+, 34.80);
Anal. calcd for C22H14ClN5O4S: C, 55.06; H, 2.94; N, 14.59.
Found: C, 55.00; H, 2.90; N, 14.55.
2.2.2.13. 4-(1-{2-[4-(Coumarin-3-yl)-1,3-thiazol-2-yl]hydraz-
inylidene}ethyl)-3-p-tolylsydnone (4m). Yield 73%, m.p. 219–
220 C. IR (KBr): t 3440 (NH), 1740 (sydnone C‚O), 1726
(coumarin C‚O), 1621 (C‚N) cm1. 1H NMR (300 MHz,
CDCl3, 25 C, TMS): d= 2.35 (s, 3H, CH3), 2.39 (s, 3H,
Ar–CH3), 6.8 (s, 1H, C50–H), 7.05–7.77 (m, 9H, Ar–H), 8.25
(s, 1H, NH) ppm; MS: m/z = 458. Anal. calcd for
C23H17N5O4S: C, 60.12; H, 3.73; N, 15.24. Found: C, 60.08;
H, 3.70; N, 15.20.
2.2.2.14. 4-(1-{2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}ethyl)-3-p-tolylsydnone (4n). Yield 78%, m.p.
179–180 C. IR (KBr): t 3448 (NH), 1742 (sydnone C‚O),
1729 (coumarin C‚O), 1636 (C‚N) cm1. 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 2.37 (s, 3H, CH3), 2.32
(s, 3H, Ar–CH3), 6.50 (s, 1H, C50–H), 7.15-7.96 (m, 8H, Ar–
H), 8.22 (s, 1H, NH) ppm; MS: m/z = 540 (M+2, 23.40),
538 (M+, 28.10). Anal. calcd for C23H16BrN5O4S: C, 51.31;
H, 3.00; N, 13.01. Found: C, 51.25; H, 2.96; N, 12.98.Activity ¼ Conc:of Maltose liberated Volume of enzyme used ðmlÞ
Mol:wt of maltose incubation times ðminÞ Dilution factor2.2.2.15. 4-(1-{2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}ethyl)-3-p-tolylsydnone (4o). Yield 72%, m.p.
243–244 C. IR (KBr): t 3446 (NH), 1740 (sydnone C‚O),
1725 (coumarin C‚O), 1632 (C‚N) cm1. 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 2.36 (s, 3H, CH3), 2.42
(s, 3H, Ar–CH3), 6.65 (s, 1H, C50–H), 7.10–7.82 (m, 8H, Ar–
H), 8.26 (s, 1H, NH) ppm; MS: m/z = 496 (M+2, 10.20),
494 (M+, 29.30). Anal. calcd for C23H16ClN5O4S: C, 55.93;
H, 3.27; N, 14.18. Found: C, 55.90; H, 3.22; N, 14.15.
2.2.2.16. 4-(1-{2-[4-(Coumarin-3-yl)-1,3-thiazol-2-yl]-hydraz-
inylidene}ethyl)-3-p-chlorophenylsydnone (4p). Yield 76%,
m.p. 188–189 C. IR (KBr): t 3431 (NH), 1743 (sydnone
C‚O), 1724 (coumarin C‚O), 1631 (C‚N) cm1. 1H
NMR (300 MHz, CDCl3, 25 C, TMS): d= 2.70 (s, 3H,
CH3), 6.70 (s, 1H, C50–H), 7.20–7.73 (m, 9H, Ar–H), 8.44 (s,
1H, NH) ppm; MS: m/z = 483 (M+2, 8.60), 481 (23.50). Anal.
calcd for C22H14ClN5O5S: C, 55.06; H, 2.94; N, 14.59. Found:
C, 55.00; H, 2.90; N, 14.55.
2.2.2.17. 4-(1-{2-[4-(6-Bromocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}ethyl)-3-p-chlorophenylsydnone (4q). Yield
80% m.p. 215–216 C, IR (KBr): t 3439 (NH), 1748 (sydnone
C‚O), 1729 (coumarin C‚O), 1642 (C‚N) cm1. 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 2.45 (s, 3H, CH3), 6.40
(s, 1H, C50–H), 7.32–7.92 (m, 8H, Ar–H), 8.45 (s, 1H, NH)
ppm; MS: m/z = 565 (M+4, 9), 563 (M+2, 29), 561 (M+,
24). Anal. calcd for C22H13BrClN5O4S: C, 47.29; H, 2.34; N,
12.53. Found: C, 47.25; H, 2.30; N, 12.50.
2.2.2.18. 4-(1-{2-[4-(6-Chlorocoumarin-3-yl)-1,3-thiazol-2-yl]-
hydrazinylidene}ethyl)-3-p-chlorophenylsydnone (4r). Yield81%, m.p. 204–205 C. IR (KBr): t 3435 (NH), 1744 (sydnone
C‚O), 1722 (coumarin C‚O), 1640 (C‚N) cm1. 1H NMR
(300 MHz, CDCl3, 25 C, TMS): d= 2.50 (s, 3H, CH3), 6.50
(s, 1H, C50–H), 7.30–7.88 (m, 8H, Ar–H), 8.40 (s, 1H, NH)
ppm; MS: m/z = 520 (M+4, 10), 518 (M+2, 26), 516 (M+,
40). Anal. calcd for C22H13Cl2N5O4S: C, 51.37; H, 2.55; N,
13.62. Found: C, 51.33; H, 2.50; N, 13.57.
2.3. Amylase inhibition assay (Sadasivam and Manickam,
1996)
The activity of amylase (Himedia, Mumbai) was assayed with
different concentrations of sample along with different vol-
umes of solvent, with control. The test tubes were added with
sodium phosphate buffer (1 ml, 50 mM, pH 7.0–7.3), different
volumes of solvent, different concentrations of sample, starch
(0.5 ml, in buffer) and enzyme (0.5 ml, from 1 mg/ml sample in
buffer). The blank tube was added with DNS (1 ml) before
adding enzyme. The tubes were incubated at 37 C for
10 min followed by addition of DNS (0.1 ml). The tubes were
incubated in boiling water bath for 10 min, cooled and read for
absorbance at 540 nm against blank. The maltose liberated
was determined by the help of standard maltose curve and
activities were calculated according to the formula,The inhibitory/induction property shown by the sample
was compared with that of control and expressed as percent
induction/inhibition. This was calculated according to the
relation,
% Inhibition=Induction ¼ Activity in presence of compound
Control activity2.4. DNA cleavage activity
2.4.1. Preparation of culture media
DNA cleavage experiments were done according to the litera-
ture (Sambrook et al., 1989). Nutrient broth [peptone, 10;
yeast extract, 5; NaCl, 10; in (g/l)] was used for culturing the
pathogen Escherichia coli. Media (50 ml) was prepared, and
autoclaved for 15 min at 121 C under 15 lb pressures. The
autoclaved media was inoculated for 24 h at 37 C.
2.4.2. Isolation of DNA
The fresh bacterial culture (1.5 ml) was centrifuged to obtain
the pellet which was then dissolved in lysis buffer (0.5 ml,
100 mM tris pH 8.0, 50 mM EDTA, 10% SDS), and saturated
phenol (0.5 ml) was added and incubated at 55 C for 10 min,
then centrifuged at 10,000 rpm for 10 min and to the superna-
tant, equal volume of chloroform: isoamyl alcohol (24:1) and
1/20th volume of 3 M sodium acetate (pH 4.8) was added.
Centrifuging at 10,000 rpm for 10 min and to the supernatant
3 volumes of chilled absolute alcohol was added. The precipi-
tated DNA was separated by centrifugation and the pellet was
dried and dissolved in TAE buffer (10 mM tris pH 8.0, 1 mM
EDTA) and stored in cold condition.
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Cleavage products were analyzed by agarose gel electropho-
resis method. Test samples (1 mg/ml) were prepared in
DMF. The samples (25 mg) were added to the isolated
DNA of E. coli. The samples were incubated for 2 h at
37 C and then DNA sample (20 ml, mixed with bromophe-
nol blue dye at 1:1 ratio) was loaded carefully into the elec-
trophoresis chamber wells along with standard DNA marker
containing TAE buffer (4.84 g tris base, pH 8.0, 0.5 M
EDTA/1 l) and ﬁnally loaded on agarose gel and constant
50 V of electricity for 45 min was passed. The gel was then
removed carefully and stained with ETBR solution (10 lg/
ml) for 10–15 min and the bands were observed under UV
transilluminator and then photographed to determine the ex-
tent of DNA cleavage. The results were compared with stan-
dard DNA marker.
3. Results and discussion
In method 1, thiosemicarbazones (2a-f) were prepared by the
reaction of 3-aryl-4-formyl/acetylsydnone (1a-f) with thiosem-
icarbazide. The title compounds (4a-r) were then obtained by
reﬂuxing (2a-f) with 3-bromoacetyl-(6-substituted)-coumarin
(3g-i) in the presence of silica sulfuric acid (5 mol%) in alcohol
under reﬂux (about 10 h) with 50–60% yield.
The method 2 has a general applicability viz., to reduce
all these steps and avoid wastage of chemicals for the prep-
aration of title compounds (4a-r). A mixture of 3-aryl-4-for-
myl/acetylsydnone (1a-f), thiosemicarbazide and 3-
bromoacetyl-6-substituted-coumarin (3g-i), was reﬂuxed inScheme 1 Formation of thiazole derivatives 4a-r. 1a-f/2a-f: 1a/2a
Ar = p-ClC6H4, R = H; 1d/2d: Ar = C6H5, R = CH3; 1e/2e: Ar = p
R0 =H; 3h: R0 = Br; 3i: R0 =Cl; 4a-r: 4a: Ar = C6H5, R = H, R0
R0 =Cl; 4d: Ar = p-CH3C6H4, R = H, R0 =H; 4e: Ar = p-CH3C6H
Ar = p-ClC6H4, R = H, R
0 =H; 4h: Ar = p-ClC6H4, R = H, R0 = B
R0 =H; 4k: Ar = C6H5, R = CH3, R0 = Br; 4l: Ar = C6H5, R = CH
CH3C6H4,, R = CH3, R
0= Br; 4o: Ar = p-CH3C6H4, R = CH3, R0 =
R= CH3, R
0 = Br; 4r: Ar = p-ClC6H4, R = CH3, R0 =Cl.the presence of silica sulfuric acid (5 mol%) in dry ethanol.
The yield of the reaction was found to be higher than that
of the method 1 and also time taken for the completion of
the reaction was reduced to a greater extent (Table 1). It is
one step three component synthesis (Scheme 1). The proba-
ble mechanism of formation of thiazole ring in the title com-
pounds (4a-r) under the inﬂuence of catalyst silica sulfuric
acid is given in the Scheme 2.
In comparison with the method 1, yield of the reaction under
one-pot catalyzed condition was higher with a less time. There-
fore, we employed the above conditions for preparation of the
title compounds in the presence of silica sulfuric acid. The
work-up with the use of catalyst is simple and the reusability
of silica sulfuric acid was also analyzed by the separation and
reloading in a new run and found that the catalyst could be re-
used several times without compromising in the productivity.
3.1. Antidiabetic activity
In this study, we have evaluated the inhibitory effects of title
compounds (4a-r) against a-amylase to elucidate the possible
use of title compounds (4a-r) as anti-hyperglycemic agents.
The compounds (4c, 4h, 4i and 4r) (with electron withdraw-
ing groups) exhibited stronger inhibitory activity against a-
amylase as compared to the control enzyme inhibitor.
Whereas, the compounds (4a, 4g, 4l and 4p) have shown
moderate activities and rest of the compounds have shown
weak inhibitory activity. The bar graph representation of
comparative activities of title compounds (4a-r) is shown
in Fig. 1.: Ar = C6H5, R = H; 1b/2b: Ar = p-CH3C6H4, R = H; 1c/2c:
-CH3C6H4, R = CH3; 1f/2f: Ar = p-ClC6H4, R = CH3, 3g-i: 3g:
= H; 4b: Ar = C6H5, R = H, R
0 =Br; 4c: Ar = C6H5, R = H,
4, R = H, R
0 = Br; 4f: Ar = p-CH3C6H4, R = H, R0 =Cl; 4g:
r; 4i: Ar = p-ClC6H4, R = H, R
0 =Cl; 4j: Ar = C6H5, R = CH3,
3, R
0 =Cl; 4m: Ar = p-CH3C6H4, R = CH3, R0 =H; 4n: Ar = p-
Cl; 4p: Ar = p-ClC6H4, R = CH3, R
0 =H; 4q: Ar = p-ClC6H4,
Scheme 2 Proposed mechanism for the formation of title compounds (4a-r) under the inﬂuence of silica sulfuric acid.
Figure 1 Amylase Inhibitory activity of Title compounds (4a-r)
Figure 2 DNA cleavage activity of the title compounds
Synthesis of 3-aryl-4-({2-[4-(6-substituted-coumarin-3-yl)-1,3-thiazol-2-yl]hydrazinylidene}methyl/ethyl) S3113.2. DNA cleavage activity
The DNA cleavage activity was determined using gel electro-
phoresis according to reported method (Sambrook et al.,
1989). The picture of the gels is presented in Fig. 2. The
gel after electrophoresis clearly revealed that, all tested com-
pounds did act on the DNA as little tailing in the bands can
be observed in treated samples. The difference was observed
in the bands of all compounds as compared to the control
DNA. This showed that the control DNA alone does not
show any apparent cleavage as compounds did. With this,
it can be concluded that the compounds inhibit the growth
of the pathogenic organism by cleaving the genome.
4. Conclusion
In conclusion, we have demonstrated a new and efﬁcient meth-
od for the synthesis of thiazole derivatised with coumarin and
S312 G. Tegginamath et al.sydnones using a catalytic amount of silica sulfuric acid. In
contrast to the other catalysts, storage and handling of this
catalyst did not require any special precautions. It could be
stored for months with the same reactivity. The method in-
volved in the present work addresses the current drive towards
green chemistry due to low cost and easy availability of the cat-
alyst, simple workup, high yield, easy handling and non-toxic-
ity of the catalyst. The preliminary in vitro anti-diabetic
activity of these novel series of thiazole derivatives has evi-
denced that some of the chlorine substituted (electron with-
drawing group) compounds have exhibited good a-amylase
inhibition and good DNA cleavage activity.Acknowledgements
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